Observational analysis reveals high attrition rates in multiple myeloma treatment, indicating a need to improve initial therapies like autologous stem cell transplants.
Key Points
Overall attrition rate at follow-up was 62.9%, indicating significant treatment discontinuation in multiple myeloma.
Median overall survival in attrited patients was 2.87 years, highlighting the impact of treatment adherence on outcomes.
Patients analyzed included 244 newly diagnosed individuals treated across one year at Tata Memorial Hospital.
Higher age and renal dysfunction were associated with increased attrition, suggesting targeted interventions may improve retention.